Hereditary angioedema is caused by an absolute deficiency or thefun ctional inactivity ofCl esterase inhibitor in pla sma. A precise diagnosis is important because, untike allergic fo rms ofmucocutan eous edema, this condition does not respe nd to epinephrine, antihistamines, or corticosteroi ds . We report the case ofa 24-year-old man who expe rienced an acut e atta ck aft er he had stopped takin g his prophylactic medication.
Introduction
Hereditary angioedema is caused by an absolute deficiency OI' the function al inactivity of Cl esterase inhibitor in plasma. It is characterized by a recurrent, circumscribed, nonpitting, subepithelial edema involving any part of the body.' Cut aneou s lesions are usually weil circums cribed, although circumoral ede ma som etimes sprea ds to the contiguous muco sa. Pain and pruritus beyond that caused by distent ion of the skin and subcutaneous tissue are unusual. Visceral involvement is manifested by severe colic followed by watery diarrhea, which usually occurs late in the course of the disease.' Hered itary angioedema present ing as a recurrent airway obstru ction caused by laryn geal edema is rare and potenti ally fatal. 1·3 The diagno sis is based primaril y on a history of episodic ang ioedema and a positive famil y history of the disease (transmission is autosomal-dominant). Acut e attack s can be precipitated by traum a, surge ry, ment al stress, and high estrogen states.' A low level of complement factor C4 is present in 80 to 85% of cases, and the diagno sis is con firm ed by low levels of C I esterase inhibitor.'
Case report
We exa mined a 24-yea r-old man who had experience d six episodes of angioedema dur ing the prev ious 20 years. All of these episodes involved varying degr ees of laryn geal edema. The patient ' s gra ndfather, father, paternal aunt, and brother had all had this condition. Th e diagno sis was confirmed by a low level « 50% of normal) of C I esterase inhibitor. Th e patient ' s latest episode occurred after he had failed to take his usual proph ylact ic dose of danazol (200 mg/day) durin g the previou s 2 weeks.
At the emergency room , the patient reported that he had experience d asudden onset ofth roat discom fort, dysphagia, and dysphonia. During the ex amination , but prior to any instrumentation of the airway, the onset of respiratory distress led to an urgent nasal fiberoptic laryn goscop y and fiberoptic ally guided intubation while the patient was awake. He was treated simultaneously with 500 U of pur ified CI esterase inhibitor conce ntrate. The patienr's epiglottis, voc al fold s, and surrounding laryngeal structures were noted to be edematous at the time of intub ation.
The pati ent rem ained intubated for 24 hours. Following extubation of the trache a, a repeat fib eroptic upper airway exa mination was undertaken unde r co ntrolled conditions. Thi s examination revealed that the patient had a posteriorly displaced tongue base seconda ry to swelling of the floor of the mouth along with edema of the epiglottis and suprag lottis (figu re). Although the edema had dim inished somew hat by the time this examin ation had been performed, the pyriform fossae were stiIl obl iterated.
Discussion
The preci se diagno sis ofhered itary ang ioedema is important because, uniik e allerg ic forms of mucocut aneous edema , hereditary angioedema does not respond to epinephrine, ant ihistamines, OI' corticostero ids. The tre atment of acute attacks is largely supportive, and prior ity is given to sec uring an adeq uate airwa y.
CI esterase inhibitor concentrate has recently become available outside Europ e, where it has become the therapy of choice for life-threatening attacks . An intraven ous infusion of 500 to 1,000 U has an onse t of action of 30 minute s to 2 hours and lasts for 3 to 5 days.' If C I esterase inhibitor conce ntrate is not available, an infusion of 2 to Dominant LethalTest (Miee) Long-term earcinogenieity studiesin mieeand rats have been eompleted for ciprotloxacin. Att er daily oral doses at 750mglkg (miee)and 250 mglkg (rats) were administered for upto 2 years, therewas noevidenee that eiprolloxaein had anyearcinogenieor tumorigeni eelleets in thesesoeees. No long term studies 01CIPRO' HCOTICsuspension havebeen pertormed to evaluateearei nogeniepotential. Ferti lity studies pertormed in rats at ora l doses at ei profl oxaein up to 100 mglkglday revealed no evidenee 01 impairment. This would be over '000 times the maximum reeommended eli nieal dose 01 atatopieal ciproüoxacin baseduponbodysurtaee area, assumingtolal absarption 01 ei profloxaei nlromthe ear 01 a patient treated with CIPRD' HCDTICtwiceper day. Long term studies have not been pert ormed to evaluate the eareinogenie potential or the elleet on lert ility01topi eal hydroeortisone. Mutagenieitystudieswith hydroeortisone were negalive. Pregnancy: Teratogenic Ellects. Pregnancy Category C: Reproductionstudieshave been pertormed in rats and miee using oral doses 01 up to ' 00 mg/kg and IV doses upto 30 mglkg and have revealed no evidenee 01 harm to theletus asaresult of eiprolloxaein. In rabbits, eiprotloxaein(30and' 00 mglkg orally)produeedgastrointestinal disturbanees res ulting in maternal wei ghtloss and an inereased incidenee01 abortion, but noteratogenieitywas observedat ei therdose. Allerintravenousadministration 01doses up to20mglkg, nomatern ai toxieitywas produeedintherabbit , andno embryotox ieity or teratogeni ei ty was observed. Cortieosteroids are generally ter atogenic in laboratory animals when adminis tered systemieally at relativelylow dosage levels. The mare patent eortieosteroids have been shown to beteratogenie atter dermai applieationin laboratory animals. Animal reproduction studies have not been eondueted wi th CIPRO' HC OTIC. No adequate and weil eontrolled studies have been pert ormed in pregnant women. Cauli on should be exereised when CI PRO' HCOTICis usedby apregnantwoman. Nursing Mothers: Ciprolloxaei n is exeretedin human milk with systemie use. It is not known whether ei profl oxaei n is exeretedin human milk lollowingtopieal otie administrat ion. 8eeause 01 thepotential lor seriousadverse reaetionsinnursing infants, adecisionshould bemadewhether todiscontinue nursingDr to di seonti nuethedrug, takingint o aeeount theimportanee01 thedrug to themother . Pedialric use: The salety and ellieacy 01 CIPRO' HC OTIC have been establ ished in pediatrie patienls 2 years and older (131 patients) in adequate and well -eontrolled elinieal trials. Although no data are available on patien ts less than age 2 years, there areno known salety eoneerns or diilerenees in the di seaseproeess inthis populalion whiehwouldpreeludeuse of thisproduetinpalients oneyear and older . See DDSAGE AND ADMINISTRATION. ADVERSE REACTIONS In Phase3 elinieal trials, a tatal 01564 patients were treated with CIPRO' HCOTIC. Adverse events with at least remote relati onship to treatment inel uded headache(1.2%) and pruritus (0.4%). The lollowing treatment-rela ted adverse events were eaeh reported in a single pati ent: migrai ne, hypesthesia. paresthesia, lungal dermatitis, cough, rash , urticaria, and alopeeia. JOYNT, ABDULLAH, WO RMALD Figure . Swelling of the base of the tongue and edema of the supraglottis obliterate the pyriformfo ssae .
4 U of fresh-frozen plasma might be useful in replacin g inhibitor levels.
Prophyl axis is recommend ed for patient s who expe rience recurre nt attac ks oflaryngeal ederna.' Danazol (50 to 600 mg/day) and stanozolol (I to 4 mg/day) have been shown to be effective. Patient s who require surgeryespec ially surge ry involving the head, neck , or respiratory tract-have a particul arly high risk of developing laryngeal angioedema . Studies have documented the effectiveness of pretreatment with danazol (600 mg/day) or stanozo lol (4 mg q6h) for 5 to 7 days preoperatively, along with e I esterase inhibitor (1,000 to 2,000 U) or fres hfroze n plasma (2 to 4 U) during the 24 hours prio r to surgery. v' Eve n wit h pro phy lac tic mea sur es, cl ose perioperative observ ation is stiil recomrn ended.'
